XIAOMI-W
01810
BABA-W
09988
ALI HEALTH
00241
BIDU-SW
09888
KUAISHOU-W
01024
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 25.64%7.54B | 4.87%13.47B | -2.67%6B | 13.65%12.85B | 19.07%6.17B | 17.36%11.3B | 40.61%5.18B | 15.17%9.63B | -7.06%3.68B | -12.38%8.36B |
Operating income | 25.64%7.54B | 4.87%13.47B | -2.67%6B | 13.65%12.85B | 19.07%6.17B | 17.36%11.3B | 40.61%5.18B | 15.17%9.63B | -7.06%3.68B | -12.38%8.36B |
Cost of sales | -24.99%-6.48B | -2.46%-11.53B | 5.43%-5.19B | -14.88%-11.25B | -23.61%-5.48B | -15.99%-9.79B | -38.32%-4.44B | -14.91%-8.44B | 8.22%-3.21B | 13.45%-7.35B |
Operating expenses | -24.99%-6.48B | -2.46%-11.53B | 5.43%-5.19B | -14.88%-11.25B | -23.61%-5.48B | -15.99%-9.79B | -38.32%-4.44B | -14.91%-8.44B | 8.22%-3.21B | 13.45%-7.35B |
Gross profit | 29.80%1.06B | 21.88%1.94B | 19.34%817.98M | 5.63%1.59B | -7.99%685.41M | 27.05%1.51B | 56.06%744.96M | 17.03%1.19B | 1.56%477.35M | -3.76%1.02B |
Selling expenses | -14.90%-246.26M | -19.31%-464.28M | 28.95%-214.34M | 33.60%-389.15M | -21.90%-301.67M | -21.80%-586.08M | -44.36%-247.48M | -22.74%-481.18M | -2.18%-171.44M | 4.07%-392.03M |
Administrative expenses | -13.97%-222.26M | -33.69%-446.08M | -28.25%-195.02M | -8.97%-333.68M | -5.62%-152.07M | -14.96%-306.21M | -20.28%-143.97M | 2.62%-266.36M | 4.18%-119.7M | -1.41%-273.53M |
Research and development expenses | -12.97%-181.54M | 2.87%-371.87M | -31.53%-160.69M | -59.90%-382.87M | 29.12%-122.17M | -38.63%-239.45M | -140.61%-172.36M | -44.72%-172.72M | -48.88%-71.63M | -7.50%-119.35M |
Revaluation surplus | -143.06%-13.68M | ---- | --31.77M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
-Changes in the fair value of other assets | -143.06%-13.68M | ---- | --31.77M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Impairment and provision | -369.87%-29.19M | 115.02%4.13M | -200.87%-6.21M | -15.80%-27.52M | -478.90%-2.07M | -14.93%-23.76M | 104.49%545K | -243.84%-20.68M | -367.42%-12.13M | -84.11%-6.01M |
-Other impairment is provision | -369.87%-29.19M | 115.02%4.13M | -200.87%-6.21M | -15.80%-27.52M | -478.90%-2.07M | -14.93%-23.76M | 104.49%545K | -243.84%-20.68M | -367.42%-12.13M | -84.11%-6.01M |
Special items of operating profit | -52.33%57.29M | -27.42%201.8M | 8.04%120.17M | 1,613.37%278.05M | 298.75%111.23M | -125.35%-18.37M | -1,026.40%-55.96M | -45.11%72.49M | -92.42%6.04M | 59.12%132.07M |
Operating profit | 8.25%426.13M | 17.28%867.41M | 80.04%393.67M | 120.23%739.61M | 73.91%218.66M | 5.00%335.84M | 15.88%125.73M | -10.29%319.83M | -47.42%108.5M | 3.24%356.53M |
Financing cost | -63.26%-160.09M | -43.10%-223.55M | -32.30%-98.06M | -8.58%-156.22M | -5.57%-74.12M | 9.04%-143.87M | 14.80%-70.21M | 20.02%-158.18M | 18.19%-82.41M | 2.27%-197.77M |
Earning before tax | -10.00%266.05M | 10.36%643.85M | 104.52%295.61M | 203.91%583.39M | 160.32%144.54M | 18.75%191.96M | 112.80%55.52M | 1.82%161.65M | -75.30%26.09M | 11.03%158.76M |
Tax | 39.76%-24.3M | 5.74%-76.02M | 16.06%-40.34M | -219.59%-80.65M | -335.44%-48.06M | -6.53%-25.24M | 13.53%-11.04M | 24.15%-23.69M | 52.59%-12.76M | -97.08%-31.23M |
After-tax profit from continuing operations | -5.30%241.75M | 12.95%567.84M | 164.58%255.27M | 201.53%502.74M | 116.88%96.48M | 20.85%166.73M | 233.78%44.49M | 8.18%137.96M | -83.06%13.33M | 0.31%127.53M |
Earning after tax | -5.30%241.75M | 12.95%567.84M | 164.58%255.27M | 201.53%502.74M | 116.88%96.48M | 20.85%166.73M | 233.78%44.49M | 8.18%137.96M | -83.06%13.33M | 0.31%127.53M |
Minority profit | -113.07%-3.07M | 49.82%32.46M | 42.84%23.51M | -29.19%21.67M | 7.47%16.46M | 115.03%30.6M | 229.47%15.32M | 381.65%14.23M | -57.94%-11.83M | -124.38%-5.05M |
Profit attributable to shareholders | 5.64%244.82M | 11.29%535.37M | 189.62%231.76M | 253.40%481.08M | 174.32%80.02M | 10.02%136.13M | 15.95%29.17M | -6.68%123.73M | -70.81%25.16M | 24.59%132.59M |
Basic earnings per share | 5.88%0.18 | 11.43%0.39 | 183.33%0.17 | 250.00%0.35 | 200.00%0.06 | 11.11%0.1 | 0.00%0.02 | -10.00%0.09 | -66.67%0.02 | 25.00%0.1 |
Diluted earnings per share | 6.25%0.17 | 8.57%0.38 | 166.67%0.16 | 250.00%0.35 | 200.00%0.06 | 11.11%0.1 | 0.00%0.02 | -10.00%0.09 | -66.67%0.02 | 25.00%0.1 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.